Cargando…

Inhibition of JAK3 with a novel, selective, and orally active small molecule induces therapeutic response in T-cell malignancies

Detalles Bibliográficos
Autores principales:	Ross, Jeremy A., Spadaro, Michela, Rosado, Damaris C., Cavallo, Federica, Kirken, Robert A., Pericle, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981915/ https://www.ncbi.nlm.nih.gov/pubmed/24153015 http://dx.doi.org/10.1038/leu.2013.309

Ejemplares similares

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
por: Caldeira, Jerri C., et al.
Publicado: (2020)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

JAK Inhibitors: Back to Small Molecules for the Treatment of IBD
por: Panés, Julian, et al.
Publicado: (2020)

The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies
por: Ross, Jeremy A., et al.
Publicado: (2017)

Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
por: Thoidingjam, Leishemba K., et al.
Publicado: (2022)

JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation
por: Rodriguez, Georgialina, et al.
Publicado: (2023)

JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling
por: Grant, Alice H., et al.
Publicado: (2023)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
por: Malemud, Charles J.
Publicado: (2010)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
por: Virtanen, Anniina T., et al.
Publicado: (2023)

The Many Faces of JAKs and STATs Within the COVID-19 Storm
por: Grant, Alice H., et al.
Publicado: (2021)

NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3
por: Kim, Byung-Hak, et al.
Publicado: (2010)

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
por: Bolli, Elisabetta, et al.
Publicado: (2017)

Phosphorylation of Tyrosine 841 Plays a Significant Role in JAK3 Activation
por: Sun, Shengjie, et al.
Publicado: (2023)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
por: Rah, Bilal, et al.
Publicado: (2022)

Small Molecule Catalysts with Therapeutic Potential
por: Ney, Yannick, et al.
Publicado: (2018)

Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies
por: Rodriguez Moncivais, Omar J., et al.
Publicado: (2023)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
por: Rolih, Valeria, et al.
Publicado: (2020)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
por: Li, Shuyu D., et al.
Publicado: (2017)

Expression of the Selected Proteins of JAK/STAT Signaling Pathway in Diseases with Oral Mucosa Involvement
por: Ociepa, Kamila, et al.
Publicado: (2022)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies
por: Morgan, Ethan L., et al.
Publicado: (2020)

Coupled small molecules target RNA interference and JAK/STAT signaling to reduce Zika virus infection in Aedes aegypti
por: Trammell, Chasity E., et al.
Publicado: (2022)

Selective small-molecule EPAC activators
por: Luchowska-Stańska, Urszula, et al.
Publicado: (2019)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease
por: Moss, Donald E, et al.
Publicado: (2013)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

How important is JAK1 selectivity?
por: Edwards, Christopher J
Publicado: (2021)

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
por: Ma, L, et al.
Publicado: (2013)

Small-Molecule Therapeutic Perspectives for the Treatment of Progeria
por: Macicior, Jon, et al.
Publicado: (2021)

Small-Molecule Inhibition of KRAS through Conformational Selection
por: Pagba, Cynthia V., et al.
Publicado: (2023)

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2019)

In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
por: Shoblock, James R., et al.
Publicado: (2019)

In Search of Small Molecules That Selectively Inhibit MBOAT4
por: Murzinski, Emily S., et al.
Publicado: (2021)

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
por: Bertsias, George
Publicado: (2020)

Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma
por: Yip, King Tuo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_10qigb6sq4mn0eb93c092s7jin